Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.

Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.

A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.

In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.

The cardiovascular-kidney-metabolic framework puts the urine albumin-to-creatinine ratio at the center of risk stratification, so that a positive result leads to earlier treatment rather than just being documented.

A panel of 4 health care professionals describe how their health systems adopted the race-free 2021 CKD-EPI equations.